EYPT

EyePoint Pharmaceuticals, Inc.

26.58 USD
+0.03 (+0.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

EyePoint Pharmaceuticals, Inc. stock is up 6.75% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 31.25% of the previous 15 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 7 PUTs, 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Feb 20:59 19 Apr, 2024 25.00 PUT 200 1910
14 Feb 15:02 19 Apr, 2024 25.00 PUT 119 2501
14 Feb 19:54 19 Jul, 2024 25.00 CALL 60 226
16 Feb 19:58 16 Feb, 2024 22.50 CALL 60 435
20 Feb 17:34 17 May, 2024 40.00 CALL 168 61
20 Feb 17:34 17 May, 2024 25.00 PUT 180 8
20 Feb 17:34 17 May, 2024 25.00 PUT 118 8
20 Feb 17:34 17 May, 2024 25.00 PUT 247 8
20 Feb 17:35 17 May, 2024 25.00 PUT 132 8
23 Feb 15:43 15 Mar, 2024 30.00 PUT 100 169

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.